Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial. Oaknin A, Moore K, Meyer T, Lopez-Picazo Gonzalez J, et al. Lancet Oncol 2024 Apr 9:S1470-2045(24)00088.

Read + Share

Amedeo Smart

Independent Medical Education